The identification of inhibitory signals, such as the ligand to PD-1 (PD-L1), led to a new class of immunotherapeutic drugs that hinders immune effector inhibition, which may reinvigorate pre-existing anti-cancer immune responses [15,16]. The gene discussed is PDCD1; the disease is cancer.